3L17

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

Summary for 3L17

• Entry DOI: 10.2210/pdb3l17/pdb
• Related: 3L13 3L16
• Descriptor: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, 4-methyl-5-(6-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine (2 entities in total)
• Functional Keywords: kinase, atp-binding, nucleotide-binding, transferase, pi3k-gamma p110 gamma
• Biological source: Homo sapiens (human)
• Cellular location: Cytoplasm : P48736
• Total number of polymer chains: 1
• Total formula weight: 111231.73

Authors

Murray, J.M.,Wiesmann, C. (deposition date: 2009-12-10, release date: 2010-02-16, Last modification date: 2023-09-06)

• Primary citation: Sutherlin, D.P.,Sampath, D.,Berry, M.,Castanedo, G.,Chang, Z.,Chuckowree, I.,Dotson, J.,Folkes, A.,Friedman, L.,Goldsmith, R.,Heffron, T.,Lee, L.,Lesnick, J.,Lewis, C.,Mathieu, S.,Nonomiya, J.,Olivero, A.,Pang, J.,Prior, W.W.,Salphati, L.,Sideris, S.,Tian, Q.,Tsui, V.,Wan, N.C.,Wang, S.,Wiesmann, C.,Wong, S.,Zhu, B.Y.; Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer.; J.Med.Chem., 53:1086-1097, 2010; PubMed: 20050669; DOI: 10.1021/jm901284w

Experimental method

X-RAY DIFFRACTION (3 Å)